# Bruce Strober

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bruce-strober/

## Facts

| Field | Value |
| --- | --- |
| Citations | 19,920 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 66 |
| i10-index | 188 |
| Last Known Institution | Yale University |
| OpenAlex ID | https://openalex.org/A5091485944 |
| ORCID iD | 0000-0002-8394-2057 |
| Works | 477 |

## Researcher papers

Showing 12 of 18.

- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis/)
- [Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial](https://scholariq.org/papers/adalimumab-therapy-for-moderate-to-severe-psoriasis-a-randomized-controlled/)
- [Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis](https://scholariq.org/papers/comparison-of-ustekinumab-and-etanercept-for-moderate-to-severe-psoriasis/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials](https://scholariq.org/papers/efficacy-and-safety-of-risankizumab-in-moderate-to-severe-plaque-psoriasis/)
- [The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest](https://scholariq.org/papers/the-retinoblastoma-protein-and-brg1-form-a-complex-and-cooperate-to-induce-cell/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis-2/)
- [Hidradenitis suppurativa](https://scholariq.org/papers/hidradenitis-suppurativa/)
- [Community differentiation of the cutaneous microbiota in psoriasis](https://scholariq.org/papers/community-differentiation-of-the-cutaneous-microbiota-in-psoriasis/)
- [Substantial Alterations of the Cutaneous Bacterial Biota in Psoriatic Lesions](https://scholariq.org/papers/substantial-alterations-of-the-cutaneous-bacterial-biota-in-psoriatic-lesions/)
- [Bimekizumab versus Secukinumab in Plaque Psoriasis](https://scholariq.org/papers/bimekizumab-versus-secukinumab-in-plaque-psoriasis/)
- [Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up](https://scholariq.org/papers/long-term-safety-of-ustekinumab-in-patients-with-moderate-to-severe-psoriasis/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Pharmaceutical studies and practices](https://scholariq.org/topics/pharmaceutical-studies-and-practices/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [Yale University](https://scholariq.org/institutions/yale-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.